Literature DB >> 16632691

Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison.

Pierre-Yves Brillet1, Valérie Paradis, Giuseppe Brancatelli, Anne-Sophie Rangheard, Yann Consigny, Aurélie Plessier, François Durand, Jacques Belghiti, Daniele Sommacale, Valérie Vilgrain.   

Abstract

OBJECTIVE: The aims of this study were to determine the feasibility and efficacy of percutaneous radiofrequency ablation in patients with hepatocellular carcinoma waiting for liver transplantation and to compare the radiologic and pathologic findings. SUBJECTS AND METHODS: Twenty-six patients with 35 hepatocellular carcinomas were addressed for transplantation. Complications of the procedures were recorded. Primary and secondary technique effectiveness and causes of exclusion from the waiting list were assessed. After transplantation, tumor recurrence was evaluated for at least 1 year in all patients. Radiologic-pathologic comparison of the explant was performed.
RESULTS: Percutaneous radiofrequency ablation was performed in 21 (81%) patients for 28 tumors. Both minor and major complications occurred in three patients (10% each per session). The rates of primary technique effectiveness, secondary technique effectiveness for percutaneous radiofrequency ablation alone (seven tumors), and combined percutaneous radiofrequency ablation and transcatheter arterial chemoembolization (three tumors) were 56%, 76%, and 86%, respectively. After a mean follow-up of 11.9 months, 16 patients (76%) received transplants, whereas five patients were excluded from the waiting list because of distant tumor progression (n =3, 14%) or other causes (n = 2, 10%). After transplantation, tumor recurred in one (6%) of 16 patients. Histopathologic examinations were performed for 13 (81%) of 16 patients and showed complete necrosis and satellite nodules in, respectively, 12 (75%) and seven (44%) of 16 tumors.
CONCLUSION: Percutaneous radiofrequency ablation can be performed on hepatocellular carcinoma patients waiting for transplantation, allows most patients to undergo transplantation, and does not impair posttransplantation outcomes. The procedure produces complete necrosis of the treated tumor in most cases but is associated with a high rate of satellite nodules.

Entities:  

Mesh:

Year:  2006        PMID: 16632691     DOI: 10.2214/AJR.04.1927

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  22 in total

1.  Measurement of intrahepatic pressure during radiofrequency ablation in porcine liver.

Authors:  Chiaki Kawamoto; Atsushi Yamauchi; Yoko Baba; Keiko Kaneko; Koji Yakabi
Journal:  J Gastroenterol       Date:  2009-11-20       Impact factor: 7.527

2.  Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.

Authors:  Dong Ho Lee; Jeong Min Lee; Pyo Nyun Kim; Yun-Jin Jang; Tae Wook Kang; Hyunchul Rhim; Jung Wook Seo; Young Joon Lee
Journal:  Eur Radiol       Date:  2019-02-15       Impact factor: 5.315

Review 3.  Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future?

Authors:  Haniee Chung; William C Chapman
Journal:  Hepat Oncol       Date:  2014-09-09

Review 4.  Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation.

Authors:  Wong Hoi She; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-14

5.  Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.

Authors:  Derek A DuBay; Charbel Sandroussi; John R Kachura; Chia Sing Ho; J Robert Beecroft; Charles M Vollmer; Anand Ghanekar; Markus Guba; Mark S Cattral; Ian D McGilvray; David R Grant; Paul D Greig
Journal:  HPB (Oxford)       Date:  2010-11-08       Impact factor: 3.647

Review 6.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Radiofrequency ablation of liver tumors.

Authors:  Shaunagh McDermott; Debra A Gervais
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

8.  High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients.

Authors:  Tan To Cheung; Sheung Tat Fan; See Ching Chan; Kenneth S H Chok; Ferdinand S K Chu; Caroline R Jenkins; Regina C L Lo; James Y Y Fung; Albert C Y Chan; William W Sharr; Simon H Y Tsang; Wing Chiu Dai; Ronnie T P Poon; Chung Mau Lo
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

9.  Evaluation of cancer treatment in the abdomen: Trends and advances.

Authors:  Silanath Peungjesada; Hubert H Chuang; Srinivasa R Prasad; Haesun Choi; Evelyne M Loyer; Yulia Bronstein
Journal:  World J Radiol       Date:  2013-03-28

Review 10.  Value of radiofrequency ablation in the treatment of hepatocellular carcinoma.

Authors:  Kai Feng; Kuan-Sheng Ma
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.